Compare e l f Beauty Inc (ELF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs State Street SPDR S&P Biotech ETF — how do they compare? e l f Beauty Inc trades at $74.89 (market cap $4.37B), while State Street SPDR S&P Biotech ETF trades at $151.36. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals.
| ELF | XBI | |
|---|---|---|
Market Cap | $4.37B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $146.67 | $164.28 |
52-Week Low | $49.57 | $85.16 |
Enterprise Value | $5.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $74.77, up 3.49% with a bullish technical signal supported by moving averages. The company shows strong revenue growth reaching $1.31B in 2025 but faces margin compression with net income margin at 1.61%. Recent earnings beats and analyst coverage skewed toward buy/hold suggest cautious optimism. Technical indicators show support at $73 and resistance at $76, with RSI neutral but ADX signaling strong trend momentum.
Outlook remains mixed: growth initiatives in skincare and international markets provide upside, but high P/E of 168.68 and margin pressures pose valuation risks. Analyst consensus target of $74.42 aligns with current price, indicating limited near-term upside. Key risks include competitive pressures and execution on brand expansion.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
